Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) receives marketing authorisation in the European Union for patients with COPD
Anti-inflammatory treatment aimed at patients with severe...
Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® in Europe and Canada
For further information
Media: General phone: +41 44 555 15 10Beatrix Benz, phone:&n...
Nycomed’s first quarter 2010 results confirm the direction
Strong growth of Key Products and in emerging markets. Impact of pantoprazole's patent expiry in May 2009 as expected.
Total net turnover d...
GE Healthcare and Nycomed to form joint venture to sell, market and distribute medical diagnostic contrast agents in Russia and CIS
For further information
Media: General phone: +41 44 555 ...
ДЕКЛАРАЦИЯ ЗА ЗАЩИТА НА ЛИЧНИТЕ ДАННИ НА УЕБСАЙТА НА ТАКЕДА
Тази Декларация за защита на личните данни се отнася до уебсайта https://www.takeda.com/bg-bg
Представителството на „Такеда ГмбХ“ в Ре...
